Table 3.
Included technology appraisals
| TA | Country | Perspective | Base-case population | Type of model | Time horizon | Interventions compared |
|---|---|---|---|---|---|---|
| NICE TA 531 [42] | UK | UK NHS | Untreated metastatic NSCLC with PD-L1 TPS ≥ 50% | Partitioned survival | 20 years | Pembrolizumab vs. CTX |
| NICE TA 557 [41] | UK | UK NHS | Untreated metastatic non-squamous NSCLC | Partitioned survival | 20 years | Pembrolizumab + CTX vs. pembrolizumab; pembrolizumab + CTX vs. CTX |
| NICE TA 584 [44] | UK | UK NHS | (1) Untreated metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS 1–49%; (2) metastatic non-squamous EGFR/ALK-positive NSCLC when targeted therapy is not an option or has failed | Partitioned survival | 20 years | Atezolizumab + CTX vs. CTX |
| NICE TA 600 [43] | UK | UK NHS | Untreated metastatic squamous NSCLC | Partitioned survival | 20 years | Pembrolizumab + CTX vs. pembrolizumab; pembrolizumab + CTX vs. CTX |
| PBAC 3.01 [47]; resubmission of PBAC 6.04 [45] | Australia | Australian healthcare system | Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS ≥ 50 | Markov | 6 years; cycle length, NR | Pembrolizumab vs. CTX |
| PBAC 6.01 [48] | Australia | Australian healthcare system | Metastatic non-squamous EGFR/ALK-negative NSCLC | Partitioned survival | 7.5 years | Atezolizumab + CTX vs. CTX |
| PBAC 6.04 [45] | Australia | Australian healthcare system | Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS ≥ 50 | Markov | 6 years; cycle length, 1 week | Pembrolizumab vs. CTX |
| PBAC 7.09 [49] | Australia | Australian healthcare system | Untreated metastatic non-squamous EGFR/ALK/ROS1-negative NSCLC with ECOG status 0 or 1 | Partitioned survival | 7.5 years | Pembrolizumab + CTX vs. pembrolizumab; pembrolizumab + CTX vs. CTX |
| PBAC 7.17 [46]; resubmission of PBAC 6.04 [45] | Australia | Australian healthcare system | Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS ≥ 50 | Markov | 6 years | Pembrolizumab vs. CTX |
| pCODR 10101 [50] | Canada | Canadian healthcare system | Untreated metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS ≥ 50% | Partitioned survival | 10 years | Pembrolizumab vs. CTX |
| pCODR 10153 [51] | Canada | Canadian healthcare system | Untreated metastatic non-squamous EGFR/ALK-negative NSCLC | Partitioned survival | 10 years | Pembrolizumab + CTX vs. CTX |
| SMC 1239/17 [53] | Scotland | Scotland payer | Metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS ≥ 50% | Partitioned survival | 20 years | Pembrolizumab vs. CTX |
| SMC 2127 [54] | Scotland | Scotland payer | Metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS < 50% or non-evaluable | Partitioned survival | 20 years | Pembrolizumab + CTX vs. CTX |
| SMC 2187 [55] | Scotland | Scotland payer | Metastatic squamous NSCLC with PD-L1 TPS < 50% or non-evaluable | Partitioned survival | 30 years | Pembrolizumab + CTX vs. CTX |
| SMC 2207 [52]; resubmission of SMC 2127 [54] | Scotland | Scotland payer | Metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS < 50% or non-evaluable | Partitioned survival | 20 years | Pembrolizumab + CTX vs. CTX |
ALK anaplastic lymphoma kinase, CTX chemotherapy, ECOG European Cooperative Oncology Group, EGFR epidermal growth factor receptor, NHS National Health Service, NICE National Institute for Health and Care Excellence, NR not reported, NSCLC non-small cell lung cancer, PBAC Pharmaceutical Benefits Advisory Committee, pCODR pan-Canadian Oncology Drug Review, PD-L1 programmed death-ligand 1, SMC Scottish Medicines Consortium, TA technology appraisal, TPS tumor proportion score